Related Experiment Video

Updated: Aug 19, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

[Is chronic hepatitis C treatment as efficient in the general population as in randomised trials?]

Cyril Hatem1, Valérie Jooste, Anne Minello

  • 1Réseau Bourguignon de lutte contre l'hépatite C, Faculté de Médecine de Dijon, 7 boulevard Jeanne d'Arc, BP 87900, 21079 Dijon. cyril-karine.hatem@wanadoo.fr

Gastroenterologie Clinique Et Biologique
|October 31, 2003
PubMed

Insights

Antiviral therapy for chronic hepatitis C (HCV) showed sustained virological response rates comparable to clinical trials in general populations. Combined interferon and ribavirine therapy significantly improved outcomes, highlighting the need for increased treatment access.

Area of Science:

  • Hepatology
  • Virology
  • Clinical Pharmacology

Context:

  • Chronic hepatitis C (HCV) affects a significant population, necessitating effective treatment strategies.
  • Real-world data on antiviral therapy effectiveness in unselected patient cohorts are crucial for clinical practice.
  • The study population comprised new anti-HCV antibody-positive patients registered in a specialized viral hepatitis registry.

Purpose:

  • To evaluate the effectiveness of antiviral therapy in a general population of patients with chronic hepatitis C.
  • To compare sustained virological response (SVR) rates between interferon monotherapy and combination therapy with ribavirine.
  • To identify factors influencing SVR and treatment discontinuation in chronic hepatitis C patients.

Summary:

  • A population-based study analyzed 1251 chronic hepatitis C cases, with 262 receiving antiviral treatment.
  • Sustained virological response rates were 18% with interferon alone and 46.9% with interferon plus ribavirine.
  • Younger age and combination therapy were associated with higher SVR; treatment discontinuation correlated with lack of response.

Impact:

  • Sustained response rates in the general population mirrored those in highly selected patients from randomized trials.
  • The findings underscore the importance of increasing the proportion of treated patients within the general population.
  • Combination therapy demonstrated superior efficacy, suggesting its broader application in managing chronic hepatitis C.
Abstract

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...